{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:53:15Z","timestamp":1791337995267,"version":"4.3.1"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Ovarian cancer (OC) is women\u2019s eighth most common cancer, bearing the highest mortality rates of all female reproductive system malignancies. Poly (ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment scenario of metastatic OC as a maintenance post platinum-based chemotherapy. Olaparib is the first PARPi developed for this disease. Results from Study 42, Study 19, SOLO2, OPINION, SOLO1, and PAOLA-1 clinical trials, led to the FDA and EMA approval of olaparib for the maintenance treatment of women with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer without platinum progression: in the platinum-sensitive recurrent OC; in the newly diagnosed setting in case Breast Cancer (BRCA) mutations and, in combination with bevacizumab, in case of BRCA mutation or deficiency of homologous recombination genes. In this review, we synthetized olaparib\u2019s pharmacokinetic and pharmacodynamic properties and its use in special populations. We summarized the efficacy and safety of the studies leading to the current approvals and discussed the future developments of this agent.<\/jats:p>","DOI":"10.3389\/fphar.2023.1162665","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:22:59Z","timestamp":1682036579000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Olaparib and advanced ovarian cancer: Summary of the past and looking into the future"],"prefix":"10.3389","volume":"14","author":[{"given":"Brigida Anna","family":"Maiorano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro Francesco Pio","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e17052","DOI":"10.1200\/JCO.2017.35.15_suppl.e17052","article-title":"Phase I study combining olaparib and tremelimumab for the treatment of women with BRCA-deficient recurrent ovarian cancer","volume":"35","author":"Adams","year":"2017","journal-title":"JCO"},{"key":"B2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S1359-6349(10)72112-1","article-title":"405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments","volume":"8","author":"Ang","year":"2010","journal-title":"Eur. J. Cancer Suppl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-13-1262","article-title":"Efficacy of chemotherapy in BRCA1\/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: A multi-institutional study","volume":"19","author":"Ang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1002\/onco.13551","article-title":"FDA approval summary: Olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S788","DOI":"10.1016\/j.annonc.2022.07.657","article-title":"529MO - phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer","volume":"33","author":"Banerjee","year":"2022","journal-title":"Ann. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","article-title":"Hypoxia-induced down-regulation of BRCA1 expression by E2Fs","volume":"65","author":"Bindra","year":"2005","journal-title":"Cancer Res."},{"key":"B8","volume-title":"Cancer stat facts: Ovarian cancer","year":""},{"key":"B9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/0008-5472.CAN-14-2593","article-title":"A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance","volume":"75","author":"Ceccaldi","year":"2015","journal-title":"Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ygyno.2022.01.015","article-title":"Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer","volume":"164","author":"Colombo","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"B11","volume-title":"Committee for medicinal products for human use (CHMP) European medicines agency (EMA). Public assessment report olaparib","year":"2014"},{"key":"B12","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/bjc.2011.555","article-title":"Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours","volume":"106","author":"Dean","year":"2012","journal-title":"Br. J. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ygyno.2017.10.007","article-title":"Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer","volume":"147","author":"Dockery","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"v485","DOI":"10.1093\/annonc\/mdz253.016","article-title":"Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)","volume":"30","author":"Drew","year":"2019","journal-title":"Ann. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S615","DOI":"10.1016\/j.annonc.2020.08.953","article-title":"814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)","volume":"31","author":"Drew","year":"2020","journal-title":"Ann. Oncol."},{"key":"B18","volume-title":"EMA Olaparib product information","year":""},{"key":"B19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"B20","volume-title":"FDA approved Olaparib","year":""},{"key":"B21","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-Ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"JCO"},{"key":"B22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","article-title":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"174","author":"Gonz\u00e1lez-Mart\u00edn","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ygyno.2021.12.016","article-title":"Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"164","author":"Harter","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, A next-generation, highly selective PARP1 inhibitor and trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"14498","DOI":"10.1021\/acs.jmedchem.1c01012","article-title":"Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs","volume":"64","author":"Johannes","year":"2021","journal-title":"J. Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: A proof-of-concept phase II study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-21-1733","article-title":"Cediranib in combination with olaparib in patients without a germline BRCA1\/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.neo.2014.04.003","article-title":"VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2","volume":"16","author":"Lim","year":"2014","journal-title":"Neoplasia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): A randomized, open-label, phase III trial","volume":"40","author":"Liu","year":"2022","journal-title":"JCO"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers","volume":"19","author":"Lord","year":"2013","journal-title":"Nat. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.3390\/ijms23073871","article-title":"The interplay between PARP inhibitors and immunotherapy in ovarian cancer: The rationale behind a new combination therapy","volume":"23","author":"Maiorano","year":"2022","journal-title":"IJMS"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1136\/ijgc-2022-003614","article-title":"Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: A systematic review and meta-analysis","volume":"32","author":"Maiorano","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e041463","DOI":"10.1136\/bmjopen-2020-041463","article-title":"Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): A study protocol","volume":"11","author":"Mansouri","year":"2021","journal-title":"BMJ Open"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11523-016-0435-8","article-title":"An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib","volume":"11","author":"Mateo","year":"2016","journal-title":"Targ. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: A multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/00498254.2017.1346332","article-title":"In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450","volume":"48","author":"McCormick","year":"2018","journal-title":"Xenobiotica"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.annonc.2021.04.023","article-title":"PARP inhibitors and newly second primary malignancies in cancer patients: A systematic review and safety meta-analysis of placebo randomized controlled trials","volume":"32","author":"Morice","year":"2021","journal-title":"Ann. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"JCO"},{"key":"B49","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP inhibitor resistance: A tug-of-war in BRCA-mutated cells","volume":"10","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"JCO"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A gynecologic oncology group study","volume":"21","author":"Ozols","year":"2003","journal-title":"JCO"},{"key":"B52","doi-asserted-by":"publisher","first-page":"FSO370","DOI":"10.4155\/fsoa-2018-0107","article-title":"GEICO1601-ROLANDO: A multicentric single arm phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer","volume":"5","author":"Perez-Fidalgo","year":"2019","journal-title":"Future Sci. OA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s12325-018-0804-z","article-title":"Pharmacokinetic effects and safety of olaparib administered with endocrine therapy: A phase I study in patients with advanced solid tumours","volume":"35","author":"Plummer","year":"2018","journal-title":"Adv. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ygyno.2021.12.025","article-title":"Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1\/BRCA2 mutation: OPINION primary analysis","volume":"164","author":"Poveda","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40262-019-00754-4","article-title":"Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and renal impairment","volume":"58","author":"Rolfo","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1111\/bcp.14283","article-title":"Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment","volume":"86","author":"Rolfo","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA A Cancer J. Clin."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1016\/j.ejca.2007.07.010","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis","volume":"43","author":"Tentori","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1200\/JCO.2020.38.15_suppl.6068","article-title":"Efficacy and safety of olaparib according to age in BRCA-1\/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23\/ENGOT-Ov21) study","volume":"38","author":"Trillsch","year":"2020","journal-title":"JCO"},{"key":"B65","volume-title":"Center for drug evalu-ation and research-clinical pharmacology and biopharmaceutics review(s), Olaparib","year":"2014"},{"key":"B66","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ygyno.2022.01.034","article-title":"Randomized CLIO\/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer","volume":"165","author":"Vanderstichele","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology\/gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"JCO"},{"key":"B68","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1349-7006.2011.02179.x","article-title":"A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors","volume":"103","author":"Yamamoto","year":"2012","journal-title":"Cancer Sci."},{"key":"B69","unstructured":"Petra: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations\n            YapT.\n            ImS.\n            SchramA.\n            SharpA.\n            BalmanaJ.\n            BairdR. D.\n          2022"},{"key":"B70","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00280-016-3106-7","article-title":"Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours","volume":"78","author":"Yonemori","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00280-019-03799-1","article-title":"Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: Results of a phase I study in Chinese patients with advanced solid tumours","volume":"83","author":"Yuan","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"979873","DOI":"10.3389\/fphar.2022.979873","article-title":"Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305","volume":"13","author":"Zheng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40262-018-0714-x","article-title":"Bridging olaparib capsule and tablet formulations using population pharmacokinetic meta-analysis in oncology patients","volume":"58","author":"Zhou","year":"2019","journal-title":"Clin. Pharmacokinet."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1162665\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:23:11Z","timestamp":1682036591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1162665\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":73,"alternative-id":["10.3389\/fphar.2023.1162665"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1162665","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1162665"}}